Virus assembly as a target for antiretroviral therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The process of HIV assembly is controlled mainly by the viral Gag proteins and represents an attractive target for new antiviral drugs that will complement vaccine development efforts and currently available therapies. In principle, inhibitors may interfere with any of the steps of the virus assembly pathway, including precursor Gag (PrGag) myristoylation, protein trafficking to the cell surface, envelope (Env) protein incorporation, viral RNA (vRNA encapsidation), triggering of virus assembly, immature particle assembly, budding, release, PrGag processing, and mature virus core morphogenesis. Efforts to interfere with these assembly steps will be reviewed. These include investigations designed to interfere with functions of the major HIV-1 Gag proteins, matrix (MA), capsid (CA), nucleocapsid (NC), and p6. Research has achieved proof-of-principle results for inhibitors of several HIV-1 assembly steps, and characterization of these and new classes of HIV assembly inhibitors will yield novel insights relevant to both the basic biology of HIV and to the development of new therapeutics for the treatment of AIDS.

Original languageEnglish (US)
Title of host publicationAdvances in HIV-1 Assembly and Release
PublisherSpringer New York
Pages185-214
Number of pages30
ISBN (Electronic)9781461477297
ISBN (Print)146147728X, 9781461477280
DOIs
StatePublished - Apr 1 2013

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)

Fingerprint Dive into the research topics of 'Virus assembly as a target for antiretroviral therapy'. Together they form a unique fingerprint.

  • Cite this

    Barklis, E. (2013). Virus assembly as a target for antiretroviral therapy. In Advances in HIV-1 Assembly and Release (pp. 185-214). Springer New York. https://doi.org/10.1007/978-1-4614-7729-7_8